PUT YOUR PATIENT AT THE CENTER WITH AKEEGA®,THE ONLY FDA-APPROVED
DUAL ACTION TABLET
FOR BRCAm mCRPC
AKEEGA® is the first-and-only FDA-approved dual action tablet combining PARP inhibition and novel hormonal therapy to provide precision medicine for patients with BRCAm mCRPC.1
Niraparib and abiraterone acetate (AKEEGA®) is a recommended treatment option by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for BRCAm mCRPC2*†
- NCCN Category 1 for patients with no prior docetaxel or NHT
- NCCN Category 2A for patients with prior docetaxel and no prior NHT
- NCCN Category 2B for patients with prior NHT and no prior docetaxel
ONCE-DAILY DUAL
ACTION TABLETS
UNDER 1 CO-PAY1
IMPROVED BENEFIT FOR PATIENTS‡ with 1L BRCAm mCRPC vs placebo + AAP1§
MANAGEABLE SAFETY
PROFILE1
§AKEEGA® is indicated with 10 mg prednisone daily.1
AKEEGA® offers two drugs under one co-pay for BRCAm mCRPC patients1
Find a Johnson & Johnson Specialist
*See the NCCN Guidelines® for detailed recommendations, including other treatment options.
†Continue ADT to maintain castrate levels of serum testosterone (<50 ng/dL).2
‡MAGNITUDE is a phase 3, randomized, double-blind, placebo-controlled, multicenter study that evaluated treatment with AKEEGA® with prednisone vs standard of care (AAP). Cohort 1 consisted of 423 subjects with mCRPC and HRR mutations, of which 225 subjects had BRCA mutations, who were randomized (1:1) to receive either AKEEGA® (N=212) or placebo and abiraterone acetate (n=211) once daily until unacceptable toxicity or progression. All patients received prednisone 10 mg daily and either received a GnRH analog or had prior bilateral orchiectomy. AKEEGA® with prednisone significantly reduced the risk of disease progression or death by 47% [HR=0.53; 95% Cl: 0.36, 0.79; P = 0.0014] in BRCAm mCRPC patients.1,3
1L = first-line; AAP = abiraterone acetate (AA) + prednisone (P); ADT = androgen deprivation therapy; BRCAm = BRCA gene-mutated; CI = confidence interval; HR = hazard ratio; HRR = homologous recombination repair; mCRPC = metastatic castration-resistant prostate cancer; NCCN = National Comprehensive Cancer Network® (NCCN®); NHT = novel hormonal therapy; PARP = poly (ADP-ribose) polymerase.
References:
- AKEEGA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.4.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed September 9, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Chi KN, Sandhu S, Smith MR, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023;S0923-7534(23)00757-3. doi:10.1016/j.annonc.2023.06.009
